Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Sitagliptin

FDA-approved product (tablet, oral), marketed as Zituvio, Brynovin, Januvia and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Sitagliptin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Hyperlipidemia
  • Myocardial infarction
  • Stroke
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Dipeptidyl peptidase 4 (dpp-4) inhibitors
FDA pharmacologic class
Dipeptidyl Peptidase 4 Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis62.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Sitagliptin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.5 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.2 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Sitagliptin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluate the Efficacy and Safety of Empagliflozin or Glimepiride Combination Therapy in Type 2 Diabetes Mellitus Patients

    NCT07365358 · start 2026-03

    Registered record
    Registry ID
    NCT07365358
    Conditions
    Diabete Type 2
    Interventions
    empagliflozin 10mg; Glimepiride 1mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-03
    Completion
    2027-08
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabete Type 2
    Interventionempagliflozin 10mg; Glimepiride 1mg
    PhasePhase 4
    Registry statusNot yet recruiting

  • Clinical Study to Determine Bioequivalence Between Two Oral Medications of Sitagliptin/Metformin in Prolonged-release Tablets With 50 mg/1000 mg in Healthy Subjects, Fast Study.

    NCT07763899 · start 2025-11-19

    Registered record
    Registry ID
    NCT07763899
    Conditions
    Bioequivalance
    Interventions
    Sitagliptin/Metformin FDC; Janumet XR
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2025-11-19
    Completion
    2025-11-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalance
    InterventionSitagliptin/Metformin FDC; Janumet XR
    PhaseNot applicable
    Registry statusCompleted

  • Effect of Add-on SGLT2i, TZD, or Combination Therapy in Type 2 Diabetes Patients on DPP4 Inhibitors

    NCT07108985 · start 2025-09

    Registered record
    Registry ID
    NCT07108985
    Conditions
    Diabetes Mellitus, Type 2; Hyperglycemia; Insulin Resistance
    Interventions
    Sitagliptin 100 mg; Sitagliptin 100 mg + Dapagliflozin 10 mg; Sitagliptin 100 mg + Dapagliflozin 10 mg; Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-09
    Completion
    2030-08-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2; Hyperglycemia; Insulin Resistance
    InterventionSitagliptin 100 mg; Sitagliptin 100 mg + Dapagliflozin 10 mg; Sitagliptin 100 mg + Dapagliflozin 10 mg; Sitagliptin 100 mg + Dapagliflozin 10 mg + Lobeglitazone 0.5 mg
    PhasePhase 4
    Registry statusNot yet recruiting

  • Effects of Empagliflozin-Metformin, Sitagliptin-Metformin, and Metformin on Adipokines in Type 2 Diabetes

    NCT07531108 · start 2024-11-15

    Registered record
    Registry ID
    NCT07531108
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Empagliflozin-Metformin; Sitagliptin-Metformin; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2024-11-15
    Completion
    2025-11-27
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionEmpagliflozin-Metformin; Sitagliptin-Metformin; Metformin
    PhasePhase 4
    Registry statusCompleted

  • Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

    NCT06246799 · start 2024-11-07

    Registered record
    Registry ID
    NCT06246799
    Conditions
    Type 2 Diabetes (Adult Onset)
    Interventions
    Tirzepatide; Pioglitazone; Sitagliptin; Metformin HCI XR
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2024-11-07
    Completion
    2029-06-30
    Enrolment
    256

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes (Adult Onset)
    InterventionTirzepatide; Pioglitazone; Sitagliptin; Metformin HCI XR
    PhasePhase 3
    Registry statusRecruiting

  • Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

    NCT07711171 · start 2024-08-19

    Registered record
    Registry ID
    NCT07711171
    Conditions
    Type 2 Diabetes Mellitus; Cognitive Impairment
    Interventions
    Canagliflozin group; Sitagliptin; Acarbose
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2024-08-19
    Completion
    2026-10-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus; Cognitive Impairment
    InterventionCanagliflozin group; Sitagliptin; Acarbose
    PhasePhase 4
    Registry statusRecruiting

  • Semaglutide and Vascular Regeneration

    NCT05870462 · start 2023-04-29

    Registered record
    Registry ID
    NCT05870462
    Conditions
    Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Obesity
    Interventions
    Semaglutide Pen Injector
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2023-04-29
    Completion
    2024-12
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtherosclerosis; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Obesity
    InterventionSemaglutide Pen Injector
    PhasePhase 4
    Registry statusUnknown

  • Bioequivalence Study of Sitagliptin Hydrochloride / Metformin Hydrochloride Extended-release Film Coated Tablets 50 mg /500 mg (FDC) in Healthy Adult Male and Female Subjects Under Fasting Conditions.

    NCT06124495 · start 2023-01-13

    Registered record
    Registry ID
    NCT06124495
    Conditions
    Bioequivalence; Diabetes Mellitus, Type 2
    Interventions
    Sitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-01-13
    Completion
    2023-02-13
    Enrolment
    58

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence; Diabetes Mellitus, Type 2
    InterventionSitagliptin/Metformin HCl 50/500 mg extended release film-coated tablet
    PhasePhase 1
    Registry statusCompleted

  • Bioequivalence Study of of Metformin HCl From Gleptomet 50/1000 mg F.C.Tablets (EVA Pharma, Egypt) and Janumet 50/1000 mg F.C.Tablets (Merck Sharp & Dohme, The Netherlands)

    NCT05798715 · start 2022-11-29

    Registered record
    Registry ID
    NCT05798715
    Conditions
    Healthy
    Interventions
    Gleptomet 50/1000(Metformin HCl & Sitagliptin); Janumet 50/1000(Metformin HCl & Sitagliptin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-11-29
    Completion
    2023-01-13
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionGleptomet 50/1000(Metformin HCl & Sitagliptin); Janumet 50/1000(Metformin HCl & Sitagliptin)
    PhasePhase 1
    Registry statusCompleted

  • Effect of Dapagliflozin vs Sitagliptin on Liver Fat Accumulation and Body Composition in Patients With Diabetes Mellitus and Liver Transplantation

    NCT05042505 · start 2022-01-01

    Registered record
    Registry ID
    NCT05042505
    Conditions
    Diabetes Mellitus; Liver Transplant; Complications
    Interventions
    Dapagliflozin 10Mg Tab; Sitagliptin 100mg
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2026-02-27
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Liver Transplant; Complications
    InterventionDapagliflozin 10Mg Tab; Sitagliptin 100mg
    PhaseNot applicable
    Registry statusCompleted

  • A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

    NCT04295005 · start 2020-11-16

    Registered record
    Registry ID
    NCT04295005
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Empagliflozin; DPP-4i; GLP-1-RA
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2020-11-16
    Completion
    2021-09-30
    Enrolment
    24,500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionEmpagliflozin; DPP-4i; GLP-1-RA
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

    NCT04916093 · start 2019-12-20

    Registered record
    Registry ID
    NCT04916093
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Vildagliptin 50 MG; Sitagliptin 100mg; MetFORMIN 1000 Mg Oral Tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-12-20
    Completion
    2020-12-15
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionVildagliptin 50 MG; Sitagliptin 100mg; MetFORMIN 1000 Mg Oral Tablet
    PhasePhase 4
    Registry statusCompleted

  • A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

    NCT04017832 · start 2019-07-29

    Registered record
    Registry ID
    NCT04017832
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Oral semaglutide; Sitagliptin; Placebo (oral semaglutide); Placebo (sitagliptin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2019-07-29
    Completion
    2021-10-27
    Enrolment
    1,441

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionOral semaglutide; Sitagliptin; Placebo (oral semaglutide); Placebo (sitagliptin)
    PhasePhase 3
    Registry statusCompleted

  • Replication of the GRADE Diabetes Trial in Healthcare Claims Data

    NCT05099198 · start 2018-09-01

    Registered record
    Registry ID
    NCT05099198
    Conditions
    Diabetes
    Interventions
    Sitagliptin; Glimepiride
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-09-01
    Completion
    2021-08-01
    Enrolment
    6,403

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionSitagliptin; Glimepiride
    PhaseNot recorded
    Registry statusCompleted

  • Comparative Bioavailability Study of Sitagliptin/Metformin 50 mg/1000 mg Tablets in Healthy Male and Female Volunteers

    NCT05549583 · start 2018-04-15

    Registered record
    Registry ID
    NCT05549583
    Conditions
    Bioequivalence; Type 2 Diabetes
    Interventions
    Sitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-04-15
    Completion
    2018-04-25
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence; Type 2 Diabetes
    InterventionSitagliptin/metformin hydrochloride (HCl) 50/1000 mg film-coated tablet
    PhasePhase 1
    Registry statusCompleted